Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ABHD17AP3 is a pseudogene in the human genome, meaning it is a segment of DNA that resembles a gene but does not encode a functional protein[2][3]. It is related in sequence to the protein-coding gene ABHD17A (an enzyme with depalmitoylase activity), but ABHD17AP3 itself is not known to be expressed as a protein nor is it associated with any therapeutic drug target activities[1][2][3][5][7]. There is no evidence that it contributes to biological processes, diseases, or serves as a biomarker or safety concern. Its main relevance is for genetic and genomic annotation rather than functional biology or drug discovery. This entry is not a valid therapeutic target—ABHD17AP3 is a pseudogene, not a molecular entity with druggable function. It is recommended to use the functional gene/protein (e.g., ABHD17A) for target analyses if applicable[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Abhydrolase domain containing 17A pseudogene 3 (ABHD17AP3).